StockData
Alkermes plc. logo

Alkermes plc. (ALKS) stock

ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30208% above fair value
$46.85+1.40 (+3.08%)

Close on Nov 18, 2026Market cap $7.86BP/E 123.3Yield –

Alkermes gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Alkermes's gross profit for the twelve months ending Jun 30, 2026 was $1.41B, up 10.0% year over year. For fiscal 2025 it was $1.28B, down 2.5% from the year before. Over ten years it grew 10.1% a year on average. The highest annual figure on record is $1.41B in fiscal 2023.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.28B-2.5%
FY2024Dec 31, 2024$1.31B-7.0%
FY2023Dec 31, 2023$1.41B+57.8%
FY2022Dec 31, 2022$893.73M-8.5%
FY2021Dec 31, 2021$976.43M+13.5%
FY2020Dec 31, 2020$860.44M-13.1%
FY2019Dec 31, 2019$990.56M+7.9%
FY2018Dec 31, 2018$917.85M+22.6%
FY2017Dec 31, 2017$748.63M+22.0%
FY2016Dec 31, 2016$613.57M+25.4%
FY2015Dec 31, 2015$489.35M+20.8%
FY2013Mar 31, 2013$405.08M+54.4%
FY2012Mar 31, 2012$262.40M+95.2%
FY2011Mar 31, 2011$134.46M+4.4%
FY2010Mar 31, 2010$128.84M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$397.90M+16.6%
Q1 FY2026Mar 31, 2026$331.33M+28.8%
Q4 FY2025Dec 31, 2025$338.34M-8.0%
Q3 FY2025Sep 30, 2025$342.59M+8.7%
Q2 FY2025Jun 30, 2025$341.20M+1.0%
Q1 FY2025Mar 31, 2025$257.31M-11.8%
Q4 FY2024Dec 31, 2024$367.87M+19.7%
Q3 FY2024Sep 30, 2024$315.04M-1.4%
Q2 FY2024Jun 30, 2024$337.66M-39.1%
Q1 FY2024Mar 31, 2024$291.73M+27.2%
Q4 FY2023Dec 31, 2023$307.35M+22.6%
Q3 FY2023Sep 30, 2023$319.44M+58.3%
Q2 FY2023Jun 30, 2023$554.15M+154.4%
Q1 FY2023Mar 31, 2023$229.43M+2.7%
Q4 FY2022Dec 31, 2022$250.75M-7.4%
Q3 FY2022Sep 30, 2022$201.73M-17.5%
Q2 FY2022Jun 30, 2022$217.86M-13.1%
Q1 FY2022Mar 31, 2022$223.39M+6.2%
Q4 FY2021Dec 31, 2021$270.85M+14.2%
Q3 FY2021Sep 30, 2021$244.58M+10.2%
Q2 FY2021Jun 30, 2021$250.59M+23.8%
Q1 FY2021Mar 31, 2021$210.41M+5.7%
Q4 FY2020Dec 31, 2020$237.07M-35.3%
Q3 FY2020Sep 30, 2020$221.88M+4.2%
Q2 FY2020Jun 30, 2020$202.48M-13.3%
Q1 FY2020Mar 31, 2020$199.01M+12.0%
Q4 FY2019Dec 31, 2019$366.25M+37.4%
Q3 FY2019Sep 30, 2019$212.92M+1.7%
Q2 FY2019Jun 30, 2019$233.65M-10.6%
Q1 FY2019Mar 31, 2019$177.74M-1.6%
Q4 FY2018Dec 31, 2018$266.65M+12.6%
Q3 FY2018Sep 30, 2018$209.31M+15.4%
Q2 FY2018Jun 30, 2018$261.23M+45.9%
Q1 FY2018Mar 31, 2018$180.67M+19.4%
Q4 FY2017Dec 31, 2017$236.86M+32.7%
Q3 FY2017Sep 30, 2017$181.33M+25.2%
Q2 FY2017Jun 30, 2017$179.07M–
Q1 FY2017Mar 31, 2017$151.37M–
Q4 FY2016Dec 31, 2016$178.56M–
Q3 FY2016Sep 30, 2016$144.79M–

More Alkermes figures

See a number that looks wrong?